Zynex Inc ZYXI.OQ reported a quarterly adjusted loss of 66 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 4 cents. The mean expectation of three analysts for the quarter was for a loss of 20 cents per share. Wall Street expected results to range from -20 cents to -19 cents per share.
Revenue fell 55.3% to $22.29 million from a year ago; analysts expected $27.38 million.
Zynex Inc's reported EPS for the quarter was a loss of 66 cents.
The company reported a quarterly loss of $20.03 million.
Zynex Inc shares had fallen by 3.5% this quarter and lost 68.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Zynex Inc is $6.00, about 58.5% above its last closing price of $2.49
This summary was machine generated from LSEG data July 31 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)